Worth Asset Management’s Aldeyra Therapeutics ALDX Stock Holding History

Worth Asset Management’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500	Closed	-$4.2K	–	104
2023 Q2	$4.2K	Hold	500	–	–	﹤0.01%	373
2023 Q1	$4.96K	Hold	500	–	–	﹤0.01%	379
2022 Q4	$3.48K	Hold	500	–	–	﹤0.01%	388
2022 Q3	$3K	Hold	500	–	–	﹤0.01%	376
2022 Q2	$2K	Hold	500	–	–	﹤0.01%	464
2022 Q1	$1K	Buy	+500	New	+$1.99K	﹤0.01%	495

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Worth Asset Management's ALDX Position: Q3 2023 in Review

Worth Asset Management sold out of Aldeyra Therapeutics (ALDX) in Q3 2023, closing a stake of 500 shares — an estimated $4.2K sold.

Worth Asset Management first reported a position in ALDX in Q1 2022 and held it in 6 quarters. The position peaked at $4.96K in Q1 2023. 120 funds tracked by Wall St. Rank hold ALDX as of Q3 2023.

Worth Asset Management reported no remaining Aldeyra Therapeutics position as of Q3 2023 after selling out during the quarter.
Worth Asset Management sold 500 Aldeyra Therapeutics shares in Q3 2023, an estimated $4.2K.
Worth Asset Management first reported a position in Aldeyra Therapeutics in Q1 2022 and held it in 6 quarters.
Worth Asset Management's Aldeyra Therapeutics position peaked at $4.96K in Q1 2023.
120 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2023.

Based on Worth Asset Management's 13F filing for Q3 2023, filed 11 Oct 2023.